Chronic neuropathic pain (arising from damages to the nervous system) is prevalent, highly debilitating as well as frequently intractable and therefore represents a major socio-economic issue worldwide. It is characterized by prominent features including spontaneous pain, allodynia (painful sensation in response to normally non-painful stimulations), and unpleasant paresthesia/dysesthesia, pointing to alterations in sensory pathways normally dedicated to the processing of non-nociceptive information. Interestingly, mounting evidence indicate that central glial cells are key players in allodynia, partly due to changes in the astrocytic capacity to scavenge extracellular glutamate and γ-aminobutyric acid (GABA), through changes in their respective transporters (EAAT and GAT). In the present study, we investigated the glial changes occurring in the dorsal column nuclei, the major target of normally innocuous sensory information, in the rat spared nerve injury (SNI) model of neuropathic pain. We report that together with a robust microglial and astrocytic reaction in the ipsilateral gracile nucleus, the GABA transporter GAT-1 is upregulated with no change in GAT-3 or glutamate transporters. Furthermore, [3H] GABA reuptake on crude synaptosome preparation shows that transporter activity is functionally increased ipsilaterally in SNI rats. This GAT-1 upregulation appears evenly distributed in the gracile nucleus and colocalizes with astrocytic activation. Neither glial activation nor GAT-1 modulation was detected in the cuneate nucleus. Together, the present results point to GABA transport in the gracile nucleus as a putative therapeutic target against abnormal sensory perceptions related to neuropathic pain.
expression of glutamate and GABA transporters in this brain region in neuropathic pain.

In the present study, we induced peripheral neuropathy using the spared nerve injury (SNI) model in rats in order to study the glial reaction and the expression of EAAT and GAT transporters in the gracile nucleus. The results indicate that, together with a microglial and astrocytic activation, a significant increase in GAT-1 expression occurs in the entirety of the ipsilateral gracile nucleus, with no detectable change in GAT-3, EAAT-1 or EAAT-2 expression.

Adult Sprague–Dawley rats, weighing 200–250 g (Charler River, France) were submitted to SNI surgery as previously described [3]. Briefly, under isoflurane anesthesia, the left sciatic nerve was exposed at the level of its trifurcation into sural, common peroneal and tibial branches. The common peroneal and tibial nerves were ligated and cut leaving the sural nerve intact. Wounds were sutured and the animals were left to recover and watched daily for any sign of stress, distress or autotomy. Sham surgery consisted in the same procedure except that all nerves were left untouched before the suturing step. Tissues were collected seven days post surgery under deep lethal pentobarbital injection. All procedures were approved by the Committee on Animal Experimentation for the canton of Vaud, Switzerland, in line with Swiss Federal Law on Animal Welfare and the recommendations of the International Association for the Study of Pain.

For immunofluorescence, rats under terminal anesthesia were perfused with phosphate buffered saline for 1 min and then with ice-cold paraformaldehyde (4% w/v in PBS) for 10 min. The brains were carefully dissected and post fixed in the same fixative overnight at 4 °C. Free floating coronal sections (30 μm thick) of the medulla oblongata were cut from the caudal to the rostral extremity using a vibratome (Leica), collected in cold PBS, and stored at 4 °C until use. For mapping experiments, each slice was stored separately starting at the first one where gracile nuclei were visible under a binocular lens (around −14.6 mm from Bregma, noted level 0 μm) until the last one (around −13.7 mm from Bregma, noted level 990 μm). For immunolabeling, all incubation solutions were prepared from the same solution as for blocking, consisting in PBS supplemented with 10% normal goat serum and 0.05% Triton X-100. The same antibodies as for Western-blots were used as follows: EAAT-1 (1/500), EAAT-2 (1/50; Abcam, USA), GAT-1 (1/500; Abcam, USA), GAT-3 (1/500; Abcam, USA), GFAP (1/1000; Millipore, USA), GAT-1 (1/500; Abcam, USA). In addition, the following antibodies were used: rabbit anti-Iba1 (1/200; Wako, Japan), mouse anti-cd11b (1/500; Setotec, UK). Secondary antibodies were Goat anti-rabbit Alexa-488 and Goat anti-mouse Cy3 (1/1000) and were used together with DAPI nuclear labeling. Blocking, primary and secondary incubations were 30 min at room temperature, over night at 4 °C and 1 h at room temperature respectively. Microphotographs were taken using an epifluorescent microscope (AxioPlan, Zeiss, Switzerland) and the Axiovision software (Zeiss). High magnification images (×40 objective) were taken using z-stack option (stacks of 10 images). This allowed the stacking and deconvoluted acquisition of photographs along the whole thickness of the slice. For each section, digital images were all processed using the same settings to improve the contrasts with no separated part of any pictures modified independently. For signal quantification, the images were analyzed by an experimenter blind to both animal group and body side of the sample using ImageJ free-ware (National Institute of Health, http://rsb.info.nih.gov/ij/). Mean pixel intensity (grey value) of GFAP or GAT-1 immunoreactivities was calculated by selecting a 0.04 mm² area in the center portion of the gracile or cuneate nucleus. Statistics were made using GraphPadPrism software (GraphPad, USA). Student’s t test was performed to compare sham and SNI samples, significance threshold was set up at p < 0.05 in all analyses.

For Western-blots analysis, rats under terminal anesthesia were decapitated and the brains were rapidly dissected to expose the medulla oblongata. Isolated samples consisted in roughly 2 mm long pieces of dorso-medial medullar tissue underneath the caudal limit of the cerebellum. Ipsilateral and contralateral samples were collected separately. Following protein extraction, Western-blots were performed using the following antibodies: rabbit against EAAT-1 (1/5000; Abcam, USA), rabbit against EAAT-2 (1/5000; Abcam, USA), rabbit against GAT-1 (1/5000; Abcam, USA), rabbit against GAT-3 (1/5000; Abcam, USA), mouse anti-GFAP (1/2000; Millipore, USA), rabbit against Iba1 (1/1000; Wako, Japan) and mouse anti-GAPDH (1/50,000; Abcam, USA). Horse radish peroxidase-conjugated secondary antibodies were used for detection (1/8000, Dako, Denmark). Blocking (30 min at room temperature) and probing (1 h at room temperature) incubations were made in 5% (w/v) non-fat milk in phosphate buffered saline (PBS) with 0.1% Tween 20. Washings were made in PBS-Tween. After washings, the membranes were incubated with ECL reagent (Pierce, USA) and exposed to a luminous image analyzer (LAS-4000, Fujifilm, Bucher, Switzerland). For subsequent GAPDH detection, the membranes were subsequently directly processed for antibody incubation. For quantification, the bands were quantified using Imagej software, signals were first normalized over GAPDH intensity and then over the mean of sham intensity. Statistics were made using GraphPadPrism software (GraphPad, USA). Student’s t test was used and threshold was set up at p < 0.05 in all analyses.

For preparation of crude synaptosomes, about 5 mm of ipsilateral and contralateral brainstem dorsal portion (straddling the caudal extremity of the fourth ventricle) were collected in ice-cold homogenization buffer (0.32 M sucrose in 10 mM HEPES). Samples were homogenized by a 10 s stroke with a rotator Miccra D1 homogenizer (Milian, Switzerland) and centrifuged (1000 g, 10 min at 4 °C) to pellet cell debris and nuclei. Supernatants were then centrifuged (15,000 g, 10 min at 4 °C) and the pellets were resuspended in incubation buffer consisting in (mM): KCl: 5.3; NaHCO3: 26.2; NaCl: 117.2; NaH2PO4: 1; d-glucose: 5.5; CaCl2: 1.2; HEPES: 1; pH 7.4. Crude synaptosomes were exposed 5 min (room temperature) to either GAT inhibitor NNC711 (Tocris, 1 μM) or the same volume of incubation buffer (vehicle). Subsequently, all samples were incubated with [3H] GABA (PerkinElmer, 50 nM, 89.5 Ci/mmol) for 5 min. Reuptake was stopped by centrifugation (15,000 g, 1 min at 4 °C) followed by 3 cycles washings/resuspensions/centrifugation in ice-cold incubation buffer. Synaptosomes were lysed in 300 μl of NaOH 0.25 M, SDS 0.1%. The incorporated radioactivity was quantified by liquid scintillation and protein content was evaluated by Bradford reaction.

In SNI animals, an augmentation in the density of Iba1 expressing microglia is noticeable ipsilaterally to the injury (Fig. 1A panels a, b). Furthermore, an astrocytic reaction is also evident as assessed by the intensification in GFAP immunoreactivity (Fig. 1A panels c, d). Additionally, a rise in cell density is also visible, as shown by the increased nuclei packing observed using DAPI labeling (Fig. 1A panels e, f). This increase in cell density might be attributable to processes of cell proliferation or division, both phenomena being known to occur in the spinal cord following neuropathy. In this regard, parallelizing what has been described in the spinal cord, the cell type accountable for this augmentation is likely to be microglia and, to a lesser extent, astrocytes [4,16]. When considering single coronal planes, the glial reaction seems to be evenly distributed throughout the gracile parenchyma. No difference in glial markers was detected between the gracile nuclei from sham animals and the contralateral one from SNI rats (not shown). Western-blot analysis confirmed the increase in GFAP in the ipsilateral tissue from neuropathic rats in comparison to sham animals (p = 0.05, n = 7 Student’s t test, Fig. 1B). Additionally, the study of GAT-1 protein showed a significant increase in GAT-1 in the ipsilateral side of SNI animals compared to the sham condition (p < 0.0001, Student’s t test,
Fig. 1. The spared nerve injury (SNI) results in a glial reaction in the ipsilateral gracile nucleus. A: Immunofluorescence analysis showing microglial Iba1 (a, b), astrocytic GFAP (c, d) and DAPI nuclear labeling (e, f) in SNI rats. An increased Iba1 and GFAP immunoreactivity as well as an increased cell density in comparison to the contralateral side is visible. Scale bar: 200 μm. B: representative images of Western-blot revealing the increased Iba1 and GFAP expression in the ipsilateral dorsal column nuclei of SNI rats. Bar histograms show GFAP band intensity, as a ratio over GAPDH and normalized over sham. *, p < 0.05 in Student’s t test, n = 7 in each group.

n = 7 in each group, Fig. 2A, B). No significant difference was found regarding EAAT-1, EAAT-2 or GAT-3 between samples from sham and SNI animals, either ipsilaterally or contralaterally (Fig. 2A). Furthermore, functional experiments on synaptosomes show that in SNI animals, the ipsilateral dorsal brainstem (containing the gracile nucleus) incorporates more [3H] GABA than contralateral tissue (2.49 × 10^6 ± 274,000 vs. 1.43 × 10^6 ± 327,000 cpm/mg proteins, p < 0.01 ANOVA followed by Dunnett’s test, n = 6 in each
Fig. 2. Peripheral neuropathy induces an increase in GAT-1 expression in the ipsilateral gracile nucleus. A: Western-blot analysis showing representative bands from SNI and sham rats, from either ipsilateral or contralateral dorsal column nuclei. An increase in GAT-1 signal in ipsilateral SNI sample is observed. B: Bar histogram showing the band quantification (same legend as in Fig. 1). ***, \( p < 0.0001 \), Student’s \( t \) test for sham vs. SNI, \( n = 7 \) in each group. C: \([\text{H}]\) GABA reuptake on brainstem synaptosomes. A significant increase in GABA incorporation is observed ipsilaterally in SNI animals in comparison to the contralateral side. No difference was detected between sham ipsilateral and contralateral samples. Preincubation with 1 \( \mu \text{M} \) NNC711 is indicated on the four last bars. **, \( p < 0.001 \), Student’s \( t \) test for sham vs. SNI, \( n = 6 \) in each group. D: Dual immunofluorescence showing the overlap (yellow) between GFAP (red, upper panels) and GAT-1 (green, upper panels) but not cd11b (red, lower panels) and GAT-1 (green, lower panels) signals. Inserts show higher magnification of a representative GFAP labeled astrocytes. Scale bar: 100 \( \mu \text{m} \).

Preincubation of synaptosomes with 1 \( \mu \text{M} \) NNC711 (a GAT blocker that selectively blocks GAT-1 at this concentration) inhibits both ipsi- and contralateral transport up to similar levels (510,600 ± 87,000 vs. 7,683,000 ± 173,800), suggesting that the increased ipsilateral GABA reuptake in SNI animals was due to GAT-1 upregulation. Importantly, dual fluorescence immunolabeling reveal that GAT-1 colocalizes with GFAP signal but not with the microglial marker cd11b (Fig. 2D).

Furthermore, we asked whether the astroglial reaction and the GAT-1 increase were present uniformly throughout the rostro-
caudal axis of the gracile nucleus. Mapping analysis shows that the augmentation in both GFAP and GAT-1 immunoreactivity are detectable all along the nucleus (Fig. 3). Interestingly, no change in GFAP or GAT-1 immunosignals could be detected in the caudate nucleus, in line with the targeted glial reaction in regions receiving inputs from the lower limb. As shown in Fig. 3E, this increase is also highlighted using immunofluorescence.

In the present study we report that a glial reaction takes place in the gracile nucleus in the SNI model of neuropathic pain, and show that it is associated with an increase in GAT-1 expression and an augmented GABA transport capacity. The GAT-1 upregulation was observed throughout the entire gracile nucleus, and was not accompanied with detectable changes in the neighboring caudate nucleus.

These advances are in accordance with previously published works showing that animal models of neuropathy were accompanied with a glial reaction in the gracile nucleus [6,8,19]. However, we report here the first study aiming at evaluating the consequences of peripheral nerve injury on the expression of transporters for neurotransmitters in the gracile nucleus. The increase in GAT-1 reported herein is of importance considering the key role played by the GABA reuptake machinery in the maintenance of normal neurotransmission, especially in the somatosensory pathway [5]. Indeed, an increased expression in GAT-1 was reported in the spinal cord of neuropathic pain models, and the associated pain hypersensitivity was reversible upon GAT-1 inhibitor administration [2]. Moreover, engineered mice devoid of the GAT-1 gene show a significant hypoalgesia [23]. It is therefore likely that the GAT-1 upregulation contributes to an augmented GABA clearance and favors disinhibition and at least partially results in a perturbation in the normally non-nociceptive signals converging to the gracile nucleus, and then in turn may account for the allodynic behaviors. Furthermore, as it has been previously highlighted that the dorsal column pathway conveys allodynic information as well [14], the observed changes might also account for the increased response to normally painful stimuli (hyperalgesia). Pharmacological antago-
nism of GAT-1 functioning at the gracile level in SNI rats, as well as GAT-1 activation in naive animals would clarify this point in the future.

Interestingly, no changes in any analyzed glutamate transporters were found in the present study. This could represent a striking difference from the spinal cord glial regulation in neuropathic pain as a drop in EAAT expression has been recurrently reported in the spinal cord in various models of chronic pain including neuropathy [1, 12, 13]. It is conceivable that the signals triggering the glial activation and transporters regulation differ between the spinal cord and the dorsal column pathway. Such signaling remains to be elucidated. Nevertheless, we cannot rule out the possibility that EAAT regulation might take place at another time point during the course of neuropathy.

The possibility that glial perturbation may take place in the dorsal column nuclei in chronic pain offers new perspective for future therapeutics aiming at selectively reducing allodynia or paresthesia/dysesthesia. Interestingly, the dorsal column pathway has emerged as a target in refractory forms of chronic pain through the development of spinal stimulation [7]. Such electrical stimulation has been shown to provide pain relief, although its precise mechanisms of action remain unknown. One possibility would be the interference with the normal physiology of the dorsal column pathway. It would be of primary importance to assess the effect of such stimulation on the glial phenotype in the gracile nucleus. Furthermore, as in the specific context of visceral hyperalgesia the dorsal column pathway has been shown to play a key role [13, 21, 22], further investigations studying the glial reaction in models of visceral pain would be highly significant.

In conclusion, the present study provides direct evidence of a strong glial reaction together with a marked increase in the GABA transporter GAT-1 in the gracile nucleus in response to peripheral nerve injury. This may have important consequences in our understanding of neuropathy-associated allodynia and paresthesia, and highlight the GABA-mediated inhibition in the dorsal column nuclei as a possible future target to alleviate these symptoms.

Acknowledgements

This work was supported by the Swiss National Science Foundation (ID) and the International Association for the Study of Pain (RDG). The authors thank Marie Pertin and Guylène Magnin for their technical assistance in the SNI surgery. We are grateful for the support provided by Pr. Christian Kern, from the Department of Anesthesiology, University Hospital Center, Lausanne.

References


